GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits ...

Zantac settlement should ease investors’ nervousness but long-standing concerns about drugmaker’s pipeline remain ...

GSK shares in London jumped 5% Thursday after the British drug giant said it has resolved most of the U.S. lawsuits it faced ...

The deal settles 80,000 US court cases related to allegations that Zantac was contaminated with a suspected carcinogen.

GSK topped the Stoxx Europe 600 index after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands ...

GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its ...

The UK's benchmark FTSE 100 opened higher on Thursday, led by gains in GSK following the settlement of lawsuits in the United ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac ...

GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of ...

FTSE 100 fluctuates after key US inflation report as the pound remains below $1.31 ...

GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future ...